MEDICURE INC (MCUJF) Form 6-K — Aug 19, 2026
Medicure reported total net revenue of $7.4 million for the quarter ended June 30, 2026, up from $6.7 million a year earlier, with adjusted EBITDA swinging to positive $172,000 from negative $28,000. Growth was driven by ZYPITAMAG sales of $2.1 million and Pharmacy Business Segment revenue of $5.9 million, including Marley Drug and the acquired West Olympia and Gateway pharmacies. AGGRASTAT revenue fell sharply to $661,000 from $1.7 million due to lower volumes and pricing competition from generic tirofiban. Net loss widened to $1.4 million, or $0.14 per share, from $786,000, or $0.08 per share, largely due to an $864,000 liability recorded for Centers for Medicare and Medicaid Services.
Key figures
- Revenue
- 7427000
- Revenue Yoy
- +11.4% vs $6.67M in Q2 2025
- Total Assets
- 22594000
- Cash Position
- 1832000
- Currency
- CAD
- Rd Expense
- 608000
- Cms Liability
- 864000
- Adjusted Ebitda
- 172000
- Six Month Revenue
- 15374000
- Aggrastat Revenue
- 661000
- Cash At Dec31 2025
- 3835000
- Prior Year Revenue
- 6669000
- Zypitamag Revenue
- 2100000
- Marley Drug Revenue
- 3400000
- West Olympia Revenue
- 1800000
- Zypitamag Marley Drug
- 1200000
- Gateway Pharmacy Revenue
- 709000
- Pharmacy Segment Revenue
- 5900000
- Zypitamag Insured Channel
- 850000
- Aggrastat Prior Year Revenue
- 1700000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.